Aby wyświetlić tę treść, wymagana jest subskrypcja JoVE. Zaloguj się lub rozpocznij bezpłatny okres próbny.
Method Article
We describe a method to produce an animal model of liver fibrosis in the rat, and assess the degree of fibrosis by histological examination of the liver. The model can be used to study the development of liver disease as well as to test the efficacy of potential anti-fibrotic agents.
Four to six week old, male Wistar rats were used to produce animal models of liver fibrosis. The process requires four weeks of administration of 10 mg/kg dimethylnitrosamine (DMN), given intraperitoneally for three consecutive days per week. Intraperitoneal injections were performed in the fume hood as DMN is a known hepatoxin and carcinogen. The model has several advantages. Firstly, liver changes can be studied sequentially or at particular stages of interest. Secondly, the stage of liver disease can be monitored by measurement of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) enzymes. Thirdly, the severity of liver damage at different stages can be confirmed by sacrifice of animals at designated time points, followed by histological examination of Masson's Trichome stained liver tissues. After four weeks of DMN dosing, the typical fibrosis score is 5 to 6 on the Ishak scale. The model can be reproduced consistently and has been widely used to assess the efficacy of potential anti-fibrotic agents.
DMN is a potent liver specific toxin. Its metabolism, tissue distribution, and ability to cause injury to livers of rats was reported by Magee1, and the mechanism of hepatocyte damage and cell death by apoptosis was described by Pritchard and Butler2. Intermittent administration of this compound was reported to induce liver fibrosis in dogs and rats3,4.
The mechanisms and morphologic changes of liver fibrosis have been extensively investigated using this model. In early studies using the rat, 3-week treatment with DMN produced centrilobular hemorrhagic necrosis followed by micronodular cirrhosis without steatosis5. It was shown that in early fibrosis, the collagen formed was more cross linked with type III being more prominent than type I6. In common with other causes, DMN-induced fibrotic changes were associated with an increase in Kupffer cells; hepatic macrophages that reside in the sinusoids. These cells morph into myofibroblasts and produce excessive amounts of extracellular matrix which is the primary problem in fibrosis7.
In terms of cellular signaling, Nakamura et al. demonstrated that TGF-β plays a critical role in the progression of liver fibrosis8. They used an adenovirus expressing a truncated type II TGF-β receptor, to specifically inhibit TGF-β signaling. Liver fibrosis in these rats was spectacularly halted during DMN treatment when compared to control groups. Other studies have confirmed that suppression of TGF-β leads to alleviation of liver fibrosis development9,10. The model was also used in a global gene profiling study to identify other fibrosis markers and proteins which could be used as drug targets for anti-fibrotic therapy11.
Other chemical agents used to induce liver fibrosis include thioacetamide (TAA) and carbon tetrachloride (CCl4). TAA was used first in rats and later in mice12. The advantages of this model include: ease of chemical administration in drinking water, the reproducibility of the model with characteristic micronodular cirrhosis and biochemical changes. The disadvantages include: the long time period of 3 months for liver fibrosis to develop and the lack of understanding of the molecular mechanism for induction of liver fibrosis. As for CCl4, its use has declined for the following reasons: it does not mimic human liver disease, has harmful effects on the ozone layer, causes pain and distress to animals, is very toxic to humans and requires extra precautions in its handling and disposal13,14.
Prolonged bile duct obstruction (by surgical intervention) as an experimental model for liver cirrhosis was first reported by Kountouras et al.15. This method is nontoxic to humans and animals. However, the time required for liver fibrosis to develop varies. A review of 30 reports by Marques et al.16, found that it took from seven days to four weeks after surgery for liver fibrosis to develop. The pathological changes described mimic those of human chronic biliary fibrosis and the model would be more suited for researchers interested in this area.
In summary, the intermittent administration of a constant dose of DMN in the rat over 4 weeks produces liver fibrosis that mimics the human disease. Dosed rats show progressive development of liver damage and parenchymal fibrosis4,17. Disease progression and severity can be monitored via blood samples or sacrifice of animals at specific time points and the effect is highly reproducible18. Thus the model has been widely used to study the mechanisms of liver fibrosis and cirrhosis as well as to screen for potential anti-fibrotic agents10,19,20.
All animal experiments were approved by the animal care and use committee of the School of Applied Science, Temasek Polytechnic.
1. Preparation of DMN
2. Intraperitoneal Injection of DMN
3. Gross Examination and Harvest of Liver
4. Processing, Embedding and Sectioning of the Liver
5. Masson Trichrome Staining
6. Fibrosis Scoring on Masson's Trichome Stained Sections of Liver
Score | Description |
0 | No fibrosis |
1 | Fibrous expansion of some portal areas, with or without short fibrous septa |
2 | Fibrous expansion of most portal areas, with or without short fibrous septa |
3 | Fibrous expansion of most portal areas, occasional portal to portal (P-P) bridging |
4 | Fibrous expansion of portal areas with marked bridging (portal to portal (P-P) as well as portal to central (P-C) |
5 | Marked bridging (P-P and/or P-C) with occasional nodules (incomplete cirrhosis) |
6 | Cirrhosis, probable or definite |
Table 1: Fibrosis Score Used for Reading the Masson's Trichome Stained Liver Sections25.
DMN treated rats lose weight and become less vigorous with ruffled hair coat. There is significant loss in average body weights of DMN treated rats; first detectable after 2 weeks of DMN treatment, and this difference remains through weeks 3 and 4 after DMN treatment (Figure 1a). As the rats receive DMN over successive weeks, damage to the liver causes it to become smaller. The liver index; which is the percent of liver weight at final body weight was significantly lower ...
We have described a method to make an animal model of liver fibrosis and to assess the severity of liver fibrosis. It is important to deliver the correct dose of DMN and adhere to the schedule of weekly intraperitoneal injections. As the experiment progresses, it is crucial to weigh the rats and re-calculate the dose at the start of each week of DMN injections. Keep in mind that DMN is toxic and needs to be handled in the fume cabinet. We perform the intraperitoneal injections in the fume cabinet as well. With the need f...
The authors declare that they have no competing financial interests.
The authors acknowledge the funding support from the Ministry of Education, Singapore, grant number MOE2010-IF-1-025.
Name | Company | Catalog Number | Comments |
Dimethylnitrosamine | Wako | 147-03781 | |
Formalin | Sinopharm chemicals | F63257009 | |
Ethanol | Sigma | 64-17-5 | |
Xylene | Fisher | 1330-20-7 | |
Masson trichome stains | |||
Aniline Blue | Electron Microscopy Sciences | #42755 | |
Acid Fuschin | Electron Microscopy Sciences | RT42685 | |
Scarlet Red | Electron Microscopy Sciences | #26905 | |
Phosphotungstic Acid Hydrate | ALFA AESAR | ALFA40116.4 | |
Phosphomolybdic Acid Hydrate | Sigma SG | 221856-25G | |
Weigert's Iron Hematoxilyn | Merck | 1.15973.0002 | |
DPX Mounting Medium | Merck | HX066873 | |
Tissue processor | Leica | Leica TP 1020 | |
Embedding machine | Sakura | Sakura Tissue Tek TEC5 Embedding System | |
Microtome | Leica | Leica RM 2235 | |
Vet Test Analyzer | Idexx | Vet Test 8008 |
Zapytaj o uprawnienia na użycie tekstu lub obrazów z tego artykułu JoVE
Zapytaj o uprawnieniaThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. Wszelkie prawa zastrzeżone